Form 4: CFO Austin Aerts Granted SERA Equity

SERA Prognostics CFO Austin Aerts received grants of 44,215 restricted stock units and 68,550 stock options with multi-year vesting schedules.

Summary

• Austin Aerts, Chief Financial Officer of SERA Prognostics, Inc. (SERA), was granted 44,215 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs have a vesting commencement date of March 10, 2026, and will vest over four years, with 1/16 of the original grant vesting in quarterly installments, subject to continued service.
• Aerts also received a grant of 68,550 stock options to purchase Class A Common Stock at an exercise price of $1.99 per share.
• These stock options have a vesting commencement date of March 10, 2026, and will vest over four years, with 1/48 of the original grant vesting in monthly installments, subject to continued service.
• Following these transactions, Aerts beneficially owns 308,667 shares of Class A Common Stock directly and 68,550 stock options directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management's interests with long-term shareholder value through equity ownership and performance incentives.

Positives

• The equity grants align the Chief Financial Officer's long-term interests with those of shareholders.
• The multi-year vesting schedules for both RSUs and stock options incentivize continued service and performance.

Negatives

• The grants do not represent immediate liquidity for the CFO, as they are subject to multi-year vesting schedules.
• The value of the equity compensation is dependent on the future performance of SERA's stock price.

Risks

• The value of the granted RSUs and stock options is subject to market fluctuations and the company's future performance.
• The reporting person must continue to provide services to the issuer for the equity awards to vest.

Future Outlook

The grants of restricted stock units and stock options, with vesting schedules extending over four years from March 10, 2026, indicate an expectation of continued service from the Chief Financial Officer and a long-term incentive structure tied to the company's future performance.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and stock options to key executives like the Chief Financial Officer is a standard practice in the biotechnology and diagnostics industry. This compensation structure is widely used to attract, retain, and motivate talent by aligning executive incentives with long-term shareholder value creation.

Comparison to Industry Standards

• Equity grants, including RSUs and stock options, are a common component of executive compensation packages across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The four-year vesting schedule for both RSUs and stock options is a typical duration designed to promote long-term retention and performance alignment.
• While the filing does not provide specific details for direct comparison, the structure of these grants is consistent with general industry practices for incentivizing senior management.

Stakeholder Impact

• Shareholders: The grants aim to align the Chief Financial Officer's interests with shareholders by tying a significant portion of compensation to the company's stock performance over the long term.
• Employees: The compensation structure may signal stability in key management roles, potentially boosting employee confidence.

Next Steps

• Austin Aerts' continued service to SERA Prognostics, Inc. is required for the vesting of the granted Restricted Stock Units and Stock Options.

Key Dates

Keywords

SERA Prognostics, SERA, Austin Aerts, CFO, Form 4, SEC filing, restricted stock units, RSU, stock options, equity grant, insider transaction, beneficial ownership, executive compensation